• 1
    Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. HEPATOLOGY 2011; 53: 1377-1387.
  • 2
    Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139: 1481-1496.
  • 3
    Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch 2007; 453: 611-620.
  • 4
    Marion TL, Leslie EM, Brouwer KL. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 2007; 4: 911-918.
  • 5
    Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. HEPATOLOGY 1999; 29: 1347-1351.
  • 6
    Roma MG, Sanchez Pozzi EJ. Oxidative stress: a radical way to stop making bile. Ann Hepatol 2008; 7: 16-33.
  • 7
    Swift B, Pfeifer ND, Brouwer KL. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 2010; 42: 446-471.
  • 8
    Copple BL, Jaeschke H, Klaassen CD. Oxidative stress and the pathogenesis of cholestasis. Semin Liver Dis 2010; 30: 195-204.
  • 9
    Perez LM, Milkiewicz P, Elias E, Coleman R, Sanchez Pozzi EJ, Roma MG. Oxidative stress induces internalization of the bile salt export pump, Bsep, and bile salt secretory failure in isolated rat hepatocyte couplets: a role for protein kinase C and prevention by protein kinase A. Toxicol Sci 2006; 91: 150-158.
  • 10
    Regal RE, Billi JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. Clin Pharm 1987; 6: 787-794.
  • 11
    Akerboom T, Schneider I, vom Dahl S, Sies H. Cholestasis and changes of portal pressure caused by chlorpromazine in the perfused rat liver. HEPATOLOGY 1991; 13: 216-221.
  • 12
    Wang EJ, Casciano CN, Clement RP, Johnson WW. Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res 2003; 20: 537-544.
  • 13
    Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010; 118: 485-500.
  • 14
    Graf J, Boyer JL. The use of isolated rat hepatocyte couplets in hepatobiliary physiology. J Hepatol 1990; 10: 387-394.
  • 15
    Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231.
  • 16
    Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001; 59: 627-635.
  • 17
    Jemnitz K, Veres Z, Vereczkey L. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol Sci 2010; 115: 80-88.
  • 18
    Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-83.
  • 19
    Antherieu S, Chesne C, Li R, Camus S, Lahoz A, Picazo L, et al. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 2010; 38: 516-525.
  • 20
    Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 2006; 28: 109-117.
  • 21
    Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. HEPATOLOGY 2007; 45: 957-967.
  • 22
    Pernelle K, Le Guevel R, Glaise D, Stasio CG, Le Charpentier T, Bouaita B, et al. Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. Toxicol Appl Pharmacol 2011; 254: 256-266.
  • 23
    Marion TL, Perry CH, St Claire RL 3rd, Brouwer KL. Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes. Toxicol Appl Pharmacol 2012; 261: 1-9.
  • 24
    Sokol RJ, Devereaux M, Khandwala RA. Effect of dietary lipid and vitamin E on mitochondrial lipid peroxidation and hepatic injury in the bile duct-ligated rat. J Lipid Res 1991; 32: 1349-1357.
  • 25
    Crocenzi FA, Mottino AD, Roma MG. Regulation of synthesis and trafficking of canalicular transporters and its alteration in acquired hepatocellular cholestasis. Experimental therapeutic strategies for its prevention. Curr Med Chem 2004; 11: 501-524.
  • 26
    Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 2003; 18: 16-22.
  • 27
    Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322-342.
  • 28
    Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011; 79: 241-250.
  • 29
    Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006; 3: 231-251.
  • 30
    Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. HEPATOLOGY 2005; 41: 1160-1172.
  • 31
    Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. HEPATOLOGY 2001; 33: 633-646.
  • 32
    Gartung C, Ananthanarayanan M, Rahman MA, Schuele S, Nundy S, Soroka CJ, et al. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996; 110: 199-209.
  • 33
    Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 2008; 36: 217-222.
  • 34
    Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002; 123: 1649-1658.
  • 35
    Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR de, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003; 278: 51085-51090.
  • 36
    Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, et al. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. HEPATOLOGY 2002; 35: 589-596.